GeneVentiv Therapeutics is developing the first universal gene therapy for all types of hemophilia and the first AAV-based gene therapy for hemophilia patients with neutralizing anti-bodies (inhibitors) to their missing clotting factor. Our lead program has an FDA Orphan Drug Designation for hemophilia A/B with or with or without inhibitors. We are raising a $20M Series A to support IND through Phase I/II.